NDA 206966 · Lnhc
Xeglyze
Abametapir · Topical
NovelDiscontinuedLast checked: Nov 20, 2026Latest source record: Jul 20, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Jul 24, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
7
2 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- XEGLYZE · ABAMETAPIR 0.74% · LOTION, TOPICAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Abametapir" as an intervention, any sponsor and status, largest first.
- A Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice InfestationPivotal-lookingCompleted
Dr. Reddy's Laboratories Limited, IndiaIndustry
NCT02060903 · 379 participants · Start Feb 2014 · Primary completion Jul 2014
Drug: Abametapir Lotion 0.74% w/w; Vehicle Lotion · For: Head Lice Infestation
Sites: Dinuba, California; Los Angeles, California; West Palm Beach, Florida · 7 sites in all
- Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice InfestationPivotal-lookingCompleted
Dr. Reddy's Laboratories Limited, IndiaIndustry
NCT02062060 · 325 participants · Start Feb 2014 · Primary completion Jul 2014
Drug: Abametapir Lotion 0.74% w/w; Vehicle Lotion · For: Head Lice Infestation
Sites: Yuma, Arizona; Los Angeles, California; Pinellas Park, Florida · 7 sites in all
- Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir LotionPivotal-lookingCompleted
Dr. Reddy's Laboratories Limited, IndiaIndustry
NCT02062073 · 238 participants · Start Jan 2014 · Primary completion Mar 2014
Drug: Abametapir Lotion 0.74% w/w · For: Head Lice
Sites: Paramus, New Jersey
Dr. Reddy's Laboratories Limited, IndiaIndustry
NCT01518699 · 57 participants · Start Jan 2012 · Primary completion May 2012
Drug: Ha44; Ha44 Placebo and 2 more · For: Pediculosis
Sites: West Bend, Wisconsin
Dr. Reddy's Laboratories Limited, IndiaIndustry
NCT02097485 · 50 participants · Start May 2014 · Primary completion Sep 2014
Drug: Abametapir Lotion 0.74% w/w; Vehicle Lotion · For: Head Lice Infestation
Sites: Ringwood East, Australia
Dr. Reddy's Laboratories Limited, IndiaIndustry
NCT02061813 · 40 participants · Start Jan 2014 · Primary completion Jan 2014
Drug: Abametapir Lotion 0.74% w/w; Sodium Lauryl Sulfate and 2 more · For: Head Lice
Sites: Paramus, New Jersey
Dr. Reddy's Laboratories Limited, IndiaIndustry
NCT02010333 · 22 participants · Start Apr 2013 · Primary completion Jul 2014
Drug: Ha44 Gel 0.74% w/w · For: Head Lice Infestation
Sites: Dinuba, California; Los Angeles, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Abametapir for the Treatment of Head Lice: A Drug Review.
Woods AD, Porter CL, Feldman SR · Ann Pharmacother 2022 · Systematic Review
- Clinical studies evaluating abametapir lotion, 0.74%, for the treatment of head louse infestation.
Bowles VM, VanLuvanee LJ, Alsop H, et al. · Pediatr Dermatol 2018 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Lnhc
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.